Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Glycogen Storage Disease Type Ia & Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for G6PC1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | G6PC1 Full-Length & Catalytic Domain Protein (WT & Disease Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View G6PC1 Products |
| Gene Delivery | G6PC1 Lentivirus Premade Particles / Promise-ORF Full-length ORF for stable cell lines (HepG2, HEK293). Codon-optimized. |
View G6PC1 Products |
| Benchmark Ab | Anti-G6PC1 Recombinant Antibody (Research Grade Control) Sequence-defined positive control for Western blot and IHC validation. |
View G6PC1 Products |
| Validator | G6PC1 siRNA Set (3 Unique Sequences) For knockdown verification and specificity control in glucose-6-phosphate output assays. |
View G6PC1 Products |
| Related Target: G6PC2 | Pancreatic Beta-Cell Isoform Critical for selectivity screening to avoid hypoglycemic off-target effects in diabetes programs. |
View G6PC2 Products |
| Related Target: G6PC3 | Ubiquitous Isoform (Immunodeficiency associated) Counter-screening target to assess systemic vs. hepatoselective inhibition. |
View G6PC3 Products |
| Related Target: SLC37A4 | G6PT (Glucose-6-Phosphate Transporter) Obligate antiporter partner; required for functional ER transport assays. |
View SLC37A4 Products |
| Related Target: GYS2 | Liver Glycogen Synthase Counter-regulatory node in glycogen metabolism; useful for metabolic flux assays. |
View GYS2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ER Membrane Topology & Complex Integration (9 TMDs) | Lentivirus-Based Stable Cell Lines (HEK293T-derived) preserving native ER insertion and topology. No VLPs required. |
| Isoform Selectivity (G6PC1 vs G6PC2 vs G6PC3) | Ortholog Panel Proteins (Human/Mouse/Rat) strictly verified by Mass Spec; >95% purity for cross-species validation. |
| Coupled Transport-Enzyme Function (SLC37A4 dependency) | Dual-Gene Co-Expression Lentivirus (G6PC1 + SLC37A4) for functional G6P transport assays. |
| Lack of High-Quality Positive Controls | Sequence-Verified Wild-Type & Catalytic Mutant (R83C, Q347X) Proteins included for rescue assays. |
| False Positives in Inhibitor Screens | Validated siRNA Set included for specificity confirmation (target knockdown vs. phenotype rescue). |
Live G6PC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (G6PC1 / Glucose-6-phosphatase)
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for G6PC1 therapeutics is bifurcating into two distinct strategies: gene therapy / enzyme replacement for Glycogen Storage Disease Type Ia (GSDIa) and small molecule inhibition for Type 2 Diabetes (T2D) and Metabolic Dysfunction-Associated Steatohepatitis (MASLD). As first-generation gene therapies (e.g., liver-directed AAV from Ultragenyx, AVROBIO) reach Phase II, the next wave of R&D is targeting isoform-selective allosteric inhibitors capable of suppressing hepatic glucose output without affecting pancreatic beta-cell function via G6PC2. The critical unmet need is the lack of biochemical assays that replicate the native ER membrane environment, driving demand for intact cell-based validation platforms. Meanwhile, mRNA therapeutics (e.g., Moderna) and substrate reduction therapy (Triheptanoin adjuvant) are also in clinical exploration. The evolving landscape calls for high-quality reagents covering wild-type, mutant, and multiple isoforms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Ultragenyx, AVROBIO | GSDIa | Functional Correction Assay (Need Full-Length G6PC1 Lentivirus for transduction efficiency testing) |
| Small Molecule Inhibitor | Structure-based discovery consortia | T2D, MASLD | Isoform Selectivity Panel (Need G6PC1/G6PC2/G6PC3 proteins with >95% purity) |
| mRNA Therapeutics (LNP) | Moderna, Academic/Startup sector | GSDIa | Expression Validation (Need Anti-G6PC1 Benchmark Abs for quantification) |
| Substrate Reduction Therapy | Ultragenyx (Triheptanoin adjuvant) | GSDIa | Pathway Analysis (Need G6PC1 siRNA for mechanistic validation) |